NA Pancreatic Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

The North America pancreatic cancer diagnostics market is projected to register a substantial CAGR of 7.7% from 2023 to 2030. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2023 to 2030.

Market Segmentation:

North America Pancreatic Cancer Diagnostics Market, By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III and Stage IV), Tumor Type(Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application(Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of pancreatic cancer diagnostics market are:

Rise in prevalence and incidence of pancreatic cancer

Increase in awareness about the pancreatic cancer diagnostics

Market Players:

Some of the major players operating in the North America pancreatic cancer diagnostics market are:

Canon Medical Systems ANZ Pty Limited.

Koninklijke Philips N.V.

Siemens Healthcare Private Limited

Grail

Myriad Genetics, Inc.

Abbott

FUJIFILM Holdings America Corporation

Agilent Technologies, Inc.

Thermo Fisher Scientific

QIAGEN

MP BIOMEDICALS

Laboratory Corporation of America Holdings

CTK Biotech, Inc.

Creative Biolabs

Meridian Life Science, Inc.

Lee Biosolutions, Inc

1 INTRODUCTION 91

1.1 OBJECTIVES OF THE STUDY 91
1.2 MARKET DEFINITION 91
1.3 OVERVIEW OF THE NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET 91
1.4 CURRENCY AND PRICING 94
1.5 LIMITATIONS 94
1.6 MARKETS COVERED 94

2 MARKET SEGMENTATION 98

2.1 MARKETS COVERED 98
2.2 GEOGRAPHICAL SCOPE 99
2.3 YEARS CONSIDERED FOR THE STUDY 100
2.4 DBMR TRIPOD DATA VALIDATION MODEL 101
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 104
2.6 MULTIVARIATE MODELLING 105
2.7 MARKET END USER COVERAGE GRID 106
2.8 PRODUCT LIFELINE CURVE 107
2.9 DBMR MARKET POSITION GRID 108
2.10 VENDOR SHARE ANALYSIS 109
2.11 SECONDARY SOURCES 110
2.12 ASSUMPTIONS 110

3 EXECUTIVE SUMMARY 111

4 PREMIUM INSIGHTS 114

4.1 PESTEL ANALYSIS 115
4.2 PORTER'S FIVE FORCES MODEL 116

5 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS 117

6 EPIDEMIOLOGY 119

7 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS 120

8 MARKET OVERVIEW 123

8.1 DRIVERS 125
- 8.1.1 GROW IN PREVALENCE OF PANCREATIC CANCER 125
- 8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS 125
- 8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 126
- 8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER 126
8.2 RESTRAINTS 127
- 8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS 127
- 8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER 127
8.3 OPPORTUNITIES 128
- 8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER 128
- 8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 129
- 8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS 129
8.4 CHALLENGES 130
- 8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 130
- 8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 130

9 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE 131

9.1 OVERVIEW 132
9.2 IMAGING TEST 135
- 9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 136
- 9.2.2 MAGNETIC RESONANCE IMAGING (MRI) 136
  - 9.2.2.1 MR CHOLANGIOPANCREATOGRAPHY 136
  - 9.2.2.2 MR ANGIOGRAPHY (MRA) 137
- 9.2.3 ULTRASOUND 137
  - 9.2.3.1 ABDOMINAL ULTRASOUND 137
  - 9.2.3.2 ENDOSCOPIC ULTRASOUND (EUS) 137
- 9.2.4 CHOLANGIOPANCREATOGRAPHY 137
  - 9.2.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP) 138
  - 9.2.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) 138
  - 9.2.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC) 138
- 9.2.5 POSITRON EMISSION TOMOHRAPHY (PET) 138
- 9.2.6 OTHERS 138
9.3 BIOPSY 139
- 9.3.1 CT-GUIDED NEEDLE BIOPSY 140
- 9.3.2 FINE NEEDLE ASPIRATION (FNA) 140
- 9.3.3 CORE NEEDLE BIOPSY 140
- 9.3.4 OTHERS 140
9.4 BLOOD TEST 140
- 9.4.1 LIVER FUNCTION TEST 141
- 9.4.2 TUMOR MARKER 141
  - 9.4.2.1 CA 19-9 BIOMARKER TEST 142
  - 9.4.2.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST 142
  - 9.4.2.3 CA 50 MARKER TEST 142
  - 9.4.2.4 OTHERS 142
- 9.4.3 OTHERS 142
9.5 GENOMIC TEST 143
9.6 OTHERS 144

10 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 145

10.1 OVERVIEW 146
10.2 STAGE IV 149
10.3 STAGE III 149
10.4 STAGE II 150
- 10.4.1 STAGE IIA 151
- 10.4.2 STAGE IIB 151
10.5 STAGE I 151
- 10.5.1 STAGE IA 152
- 10.5.2 STAGE IB 152
10.6 STAGE 0 153

11 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 154

11.1 OVERVIEW 155
11.2 EXOCRINE TUMORS 158
- 11.2.1 INSTRUMENT-BASED PRODUCTS 159
- 11.2.2 PLATFORM-BASED PRODUCTS 159
- 11.2.3 KITS AND REAGENTS 159
- 11.2.4 OTHER CONSUMABLES 159
11.3 NEUROENDOCRINE TUMORS 159
- 11.3.1 INSTRUMENT-BASED PRODUCTS 160
- 11.3.2 PLATFORM-BASED PRODUCTS 160
- 11.3.3 KITS AND REAGENTS 161
- 11.3.4 OTHER CONSUMABLES 161

12 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT 162

12.1 OVERVIEW 163
12.2 INSTRUMENT-BASED PRODUCTS 166
- 12.2.1 IMAGING 167
- 12.2.2 BIOPSY 167
12.3 PLATFORM-BASED PRODUCTS 167
- 12.3.1 NEXT-GENERATION SEQUENCING 168
- 12.3.2 MICROARRAYS 168
- 12.3.3 PCR 168
- 12.3.4 OTHERS 169
12.4 KITS AND REAGENTS 169
- 12.4.1 CA19-9 PANCREATIC CANCER TEST KITS 170
  - 12.4.1.1 ELISA TEST KITS 170
  - 12.4.1.2 CASETTE TEST KITS 170
  - 12.4.1.3 OTHERS 170
- 12.4.2 CEA PANCREATIC CANCER TEST KITS 171
  - 12.4.2.1 ELISA TEST KITS 171
  - 12.4.2.2 CASETTE TEST KITS 171
  - 12.4.2.3 OTHERS 171
12.5 OTHER CONSUMABLES 171

13 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 173

13.1 OVERVIEW 174
13.2 FLUORESCENT IN SITU HYBRIDIZATION 177
13.3 NEXT GENERATION SEQUENCING 178
13.4 FLUORIMMUNOASSAY 179
13.5 COMPARATIVE GENOMIC HYBRIDIZATION 180
13.6 IMMUNOHISTOCHEMICAL 181
13.7 OTHERS 182

14 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION 183

14.1 OVERVIEW 184
14.2 SCREENING 187
- 14.2.1 INSTRUMENT-BASED PRODUCTS 188
- 14.2.2 PLATFORM-BASED PRODUCTS 188
- 14.2.3 KITS AND REAGENTS 188
- 14.2.4 OTHER CONSUMABLES 188
14.3 DIAGNOSTIC AND PREDICTIVE 188
- 14.3.1 INSTRUMENT-BASED PRODUCTS 189
- 14.3.2 PLATFORM-BASED PRODUCTS 189
- 14.3.3 KITS AND REAGENTS 189
- 14.3.4 OTHER CONSUMABLES 189
14.4 PROGNOSTIC 190
- 14.4.1 INSTRUMENT-BASED PRODUCTS 191
- 14.4.2 PLATFORM-BASED PRODUCTS 191
- 14.4.3 KITS AND REAGENTS 191
- 14.4.4 OTHER CONSUMABLES 191
14.5 RESEARCH 191
- 14.5.1 INSTRUMENT-BASED PRODUCTS 192
- 14.5.2 PLATFORM-BASED PRODUCTS 192
- 14.5.3 KITS AND REAGENTS 192
- 14.5.4 OTHER CONSUMABLES 192

15 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER 193

15.1 OVERVIEW 194
15.2 HOSPITALS 197
15.3 DIAGNOSTIC CENTERS 197
15.4 CANCER RESEARCH CENTERS 198
15.5 ACADEMIC INSTITUTES 199
15.6 AMBULATORY SURGICAL CENTERS 200
15.7 OTHERS 201

16 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 202

16.1 OVERVIEW 203
16.2 DIRECT TENDER 206
16.3 RETAIL SALES 207
16.4 OTHERS 208

17 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION 209

17.1 NORTH AMERICA 210
- 17.1.1 U.S. 224
- 17.1.2 CANADA 233
- 17.1.3 MEXICO 242

18 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 251

18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 251

19 SWOT ANALYSIS 252

20 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET 253

20.1 CANON MEDICAL SYSTEMS CORPORATION 253
- 20.1.1 COMPANY SNAPSHOT 253
- 20.1.2 REVENUE ANALYSIS 253
- 20.1.3 COMPANY SHARE ANALYSIS 254
- 20.1.4 PRODUCT PORTFOLIO 254
- 20.1.5 RECENT DEVELOPMENT 254
20.2 KONINKLIJKE PHILIPS N.V. 255
- 20.2.1 COMPANY SNAPSHOT 255
- 20.2.2 REVENUE ANALYSIS 255
- 20.2.3 COMPANY SHARE ANALYSIS 256
- 20.2.4 PRODUCT PORTFOLIO 256
- 20.2.5 RECENT DEVELOPMENTS 256
20.3 SIEMENS HEALTHCARE GMBH 258
- 20.3.1 COMPANY SNAPSHOT 258
- 20.3.2 REVENUE ANALYSIS 258
- 20.3.3 COMPANY SHARE ANALYSIS 259
- 20.3.4 PRODUCT PORTFOLIO 259
- 20.3.5 RECENT DEVELOPMENT 260
20.4 GRAIL 261
- 20.4.1 COMPANY PROFILE 261
- 20.4.2 COMPANY SHARE ANALYSIS 261
- 20.4.3 PRODUCT PORTFOLIO 262
- 20.4.4 RECENT DEVELOPMENT 262
20.5 MYRIAD GENETICS, INC. 263
- 20.5.1 COMPANY SNAPSHOT 263
- 20.5.2 REVENUE ANALYSIS 263
- 20.5.3 COMPANY SHARE ANALYSIS 264
- 20.5.4 PRODUCT PORTFOLIO 264
- 20.5.5 RECENT DEVELOPMENT 264
20.6 BD 265
- 20.6.1 COMPANY SNAPSHOT 265
- 20.6.2 REVENUE ANALYSIS 265
- 20.6.3 PRODUCT PORTFOLIO 266
- 20.6.4 RECENT DEVELOPMENT 266
20.7 BODITECH MED INC. 267
- 20.7.1 COMPANY PROFILE 267
- 20.7.2 PRODUCT PORTFOLIO 267
- 20.7.3 RECENT DEVELOPMENT 267
20.8 ABBOTT (2022) 268
- 20.8.1 COMPANY SNAPSHOT 268
- 20.8.2 REVENUE ANALYSIS 268
- 20.8.3 PRODUCT PORTFOLIO 269
- 20.8.4 RECENT DEVELOPMENT 269
20.9 FUJIFILM HOLDINGS AMERICA CORPORATION 270
- 20.9.1 COMPANY SNAPSHOT 270
- 20.9.2 REVENUE ANALYSIS 270
- 20.9.3 PRODUCT PORTFOLIO 271
- 20.9.4 RECENT DEVELOPMENT 271
20.10 ACCUBIOTECH CO., LTD. 272
- 20.10.1 COMPANY PROFILE 272
- 20.10.2 PRODUCT PORTFOLIO 272
- 20.10.3 RECENT DEVELOPMENTS 272
20.11 AGILENT TECHNOLOGIES, INC. 273
- 20.11.1 COMPANY PROFILE 273
- 20.11.2 REVENUE ANALYSIS 273
- 20.11.3 PRODUCT PORTFOLIO 274
- 20.11.4 RECENT DEVELOPMENT 274
20.12 CREATIVE BIOLABS. 275
- 20.12.1 COMPANY PROFILE 275
- 20.12.2 PRODUCT PORTFOLIO 275
- 20.12.3 RECENT DEVELOPMENT 275
20.13 CTK BIOTECH, INC. 276
- 20.13.1 COMPANY PROFILE 276
- 20.13.2 PRODUCT PORTFOLIO 276
- 20.13.3 RECENT DEVELOPMENT 276
20.14 DIASOURCE 277
- 20.14.1 COMPANY SNAPSHOT 277
- 20.14.2 PRODUCT PORTFOLIO 277
- 20.14.3 RECENT DEVELOPMENT 277
20.15 LABORATORY CORPORATION OF AMERICA HOLDINGS 278
- 20.15.1 COMPANY SNAPSHOT 278
- 20.15.2 REVENUE ANALYSIS 278
- 20.15.3 PRODUCT PORTFOLIO 279
- 20.15.4 RECENT DEVELOPMENTS 279
20.16 LEE BIOSCIENCE 280
- 20.16.1 COMPANY SNAPSHOT 280
- 20.16.2 PRODUCT PORTFOLIO 280
- 20.16.3 RECENT DEVELOPMENT 280
20.17 MERIDIAN BIOSCIENCE INC. 281
- 20.17.1 COMPANY PROFILE 281
- 20.17.2 PRODUCT PORTFOLIO 281
- 20.17.3 RECENT DEVELOPMENT 281

20.18 MP BIOMEDICALS. 282
- 20.18.1 COMPANY PROFILE 282
- 20.18.2 PRODUCT PORTFOLIO 282
- 20.18.3 RECENT DEVELOPMENTS 282
20.19 QIAGEN 283
- 20.19.1 COMPANY SNAPSHOT 283
- 20.19.2 REVENUE ANALYSIS 283
- 20.19.3 PRODUCT PORTFOLIO 284
- 20.19.4 RECENT DEVELOPMENT 284
20.20 SETIA SCIENTIFIC SOLUTION 285
- 20.20.1 COMPANY PROFILE 285
- 20.20.2 PRODUCT PORTFOLIO 285
- 20.20.3 RECENT DEVELOPMENTS 285
20.21 THERMO FISHER SCIENTIFIC INC. 286
- 20.21.1 COMPANY SNAPSHOT 286
- 20.21.2 REVENUE ANALYSIS 286
- 20.21.3 PRODUCT PORTFOLIO 287
- 20.21.4 RECENT DEVELOPMENT 287

21 QUESTIONNAIRE 288

22 RELATED REPORTS 292

LIST OF TABLES

TABLE 1 APPROVED DIAGNOSTICS OF PANCREATIC CANCER 62
TABLE 2 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 68
TABLE 3 NORTH AMERICA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 69
TABLE 4 NORTH AMERICA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 70
TABLE 5 NORTH AMERICA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 70
TABLE 6 NORTH AMERICA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 71
TABLE 7 NORTH AMERICA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 72
TABLE 8 NORTH AMERICA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 9 NORTH AMERICA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 74
TABLE 10 NORTH AMERICA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 11 NORTH AMERICA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 75
TABLE 12 NORTH AMERICA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 76
TABLE 13 NORTH AMERICA GENOMIC TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 77
TABLE 14 NORTH AMERICA OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 78
TABLE 15 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 82
TABLE 16 NORTH AMERICA STAGE IV IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 17 NORTH AMERICA STAGE III IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
TABLE 18 NORTH AMERICA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 19 NORTH AMERICA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 85
TABLE 20 NORTH AMERICA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 21 NORTH AMERICA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 86
TABLE 22 NORTH AMERICA STAGE 0 IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 23 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 91
TABLE 24 NORTH AMERICA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 92
TABLE 25 NORTH AMERICA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 93
TABLE 26 NORTH AMERICA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 94
TABLE 27 NORTH AMERICA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 94
TABLE 28 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 99
TABLE 29 NORTH AMERICA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 100
TABLE 30 NORTH AMERICA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 101
TABLE 31 NORTH AMERICA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 102
TABLE 32 NORTH AMERICA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 102
TABLE 33 NORTH AMERICA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 103
TABLE 34 NORTH AMERICA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 104
TABLE 35 NORTH AMERICA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 104
TABLE 36 NORTH AMERICA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 105
TABLE 37 NORTH AMERICA OTHER CONSUMABLES IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 106
TABLE 38 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 110
TABLE 39 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 111
TABLE 40 NORTH AMERICA NEXT GENERATION SEQUENCING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 112
TABLE 41 NORTH AMERICA FLUORIMMUNOASSAY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 113
TABLE 42 NORTH AMERICA COMPARATIVE GENOMIC HYBRIDIZATION IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 114
TABLE 43 NORTH AMERICA IMMUNOHISTOCHEMICAL IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 115
TABLE 44 NORTH AMERICA OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 116
TABLE 45 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 120
TABLE 46 NORTH AMERICA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 121
TABLE 47 NORTH AMERICA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 121
TABLE 48 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 123
TABLE 49 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 123
TABLE 50 NORTH AMERICA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 124
TABLE 51 NORTH AMERICA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 124
TABLE 52 NORTH AMERICA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 126
TABLE 53 NORTH AMERICA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 126
TABLE 54 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 130
TABLE 55 NORTH AMERICA HOSPITALS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 131
TABLE 56 NORTH AMERICA DIAGNOSTIC CENTERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 132
TABLE 57 NORTH AMERICA CANCER RESEARCH CENTERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 132
TABLE 58 NORTH AMERICA ACADEMIC INSTITUTES IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 133
TABLE 59 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 134
TABLE 60 NORTH AMERICA OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 135
TABLE 61 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 139
TABLE 62 NORTH AMERICA DIRECT TENDER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 140
TABLE 63 NORTH AMERICA RETAIL SALES IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 141
TABLE 64 NORTH AMERICA OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 142
TABLE 65 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 149
TABLE 66 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
TABLE 67 NORTH AMERICA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 150
TABLE 68 NORTH AMERICA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 150
TABLE 69 NORTH AMERICA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 150
TABLE 70 NORTH AMERICA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 150
TABLE 71 NORTH AMERICA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 151
TABLE 72 NORTH AMERICA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 151
TABLE 73 NORTH AMERICA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 151
TABLE 74 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 151
TABLE 75 NORTH AMERICA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 152
TABLE 76 NORTH AMERICA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 152
TABLE 77 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 152
TABLE 78 NORTH AMERICA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 152
TABLE 79 NORTH AMERICA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 153
TABLE 80 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 153
TABLE 81 NORTH AMERICA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 153
TABLE 82 NORTH AMERICA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 153
TABLE 83 NORTH AMERICA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 154
TABLE 84 NORTH AMERICA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 154
TABLE 85 NORTH AMERICA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 154
TABLE 86 NORTH AMERICA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 154
TABLE 87 NORTH AMERICA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 155
TABLE 88 NORTH AMERICA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 155
TABLE 89 NORTH AMERICA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 155
TABLE 90 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 155
TABLE 91 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 156
TABLE 92 NORTH AMERICA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 156
TABLE 93 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 156
TABLE 94 NORTH AMERICA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 156
TABLE 95 NORTH AMERICA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 157
TABLE 96 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 157
TABLE 97 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 157
TABLE 98 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 158
TABLE 99 U.S. IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 158
TABLE 100 U.S. MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 158
TABLE 101 U.S. ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 159
TABLE 102 U.S. CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 159
TABLE 103 U.S. BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 159
TABLE 104 U.S. TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 159
TABLE 105 U.S. BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 160
TABLE 106 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 160
TABLE 107 U.S. STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 160
TABLE 108 U.S. STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 160
TABLE 109 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 161
TABLE 110 U.S. EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 161
TABLE 111 U.S. NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 161
TABLE 112 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 161
TABLE 113 U.S. INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 162
TABLE 114 U.S. INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 162
TABLE 115 U.S. INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 162
TABLE 116 U.S. PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 162
TABLE 117 U.S. PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 162
TABLE 118 U.S. PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 163
TABLE 119 U.S. KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 163
TABLE 120 U.S. CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 163
TABLE 121 U.S. CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 163
TABLE 122 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 164
TABLE 123 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 164
TABLE 124 U.S. SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 164
TABLE 125 U.S. DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
TABLE 126 U.S. PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
TABLE 127 U.S. RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
TABLE 128 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 166
TABLE 129 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 166
TABLE 130 CANADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 167
TABLE 131 CANADA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 167
TABLE 132 CANADA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 167
TABLE 133 CANADA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 168
TABLE 134 CANADA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 168
TABLE 135 CANADA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 168
TABLE 136 CANADA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 168
TABLE 137 CANADA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 169
TABLE 138 CANADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 169
TABLE 139 CANADA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 169
TABLE 140 CANADA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 169
TABLE 141 CANADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 170
TABLE 142 CANADA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 170
TABLE 143 CANADA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 170
TABLE 144 CANADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 170
TABLE 145 CANADA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 171
TABLE 146 CANADA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 171

LIST OF FIGURES

FIGURE 1 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: SEGMENTATION 31
FIGURE 2 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 34
FIGURE 3 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 35
FIGURE 4 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 36
FIGURE 5 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 36
FIGURE 6 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 37
FIGURE 7 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 39
FIGURE 8 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 41
FIGURE 9 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 42
FIGURE 10 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: SEGMENTATION 46
FIGURE 11 GROWING AWARENESS OF PANCREATIC CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030 47
FIGURE 12 IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET IN 2023 & 2030 47
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET 57
FIGURE 14 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022 65
FIGURE 15 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 66
FIGURE 16 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 66
FIGURE 17 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 67
FIGURE 18 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2022 79
FIGURE 19 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2023-2030 (USD MILLION) 80
FIGURE 20 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, CAGR (2023-2030) 80
FIGURE 21 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, LIFELINE CURVE 81
FIGURE 22 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, 2022 88
FIGURE 23 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION) 89
FIGURE 24 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, CAGR (2023-2030) 89
FIGURE 25 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, LIFELINE CURVE 90
FIGURE 26 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2022 96
FIGURE 27 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2023-2030 (USD MILLION) 97
FIGURE 28 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, CAGR (2023-2030) 97
FIGURE 29 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, LIFELINE CURVE 98
FIGURE 30 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2022 107
FIGURE 31 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 108
FIGURE 32 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, CAGR (2023-2030) 108
FIGURE 33 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, LIFELINE CURVE 109
FIGURE 34 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2022 117
FIGURE 35 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 118
FIGURE 36 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2023-2030) 118
FIGURE 37 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE 119
FIGURE 38 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, 2022 127
FIGURE 39 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 128
FIGURE 40 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 128
FIGURE 41 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 129
FIGURE 42 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 136
FIGURE 43 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 137
FIGURE 44 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 137
FIGURE 45 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 138
FIGURE 46 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 144
FIGURE 47 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 146
FIGURE 48 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 146
FIGURE 49 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 147
FIGURE 50 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: CATEGORY (2023-2030) 147
FIGURE 51 NORTH AMERICA PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 184